, Volume 205, Issue 3, pp 399–407 | Cite as

The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum

  • J. SarrisEmail author
  • D. J. Kavanagh
  • G. Byrne
  • K. M. Bone
  • J. Adams
  • G. Deed
Original Investigation



Piper methysticum (Kava) has been withdrawn in European, British, and Canadian markets due to concerns over hepatotoxic reactions. The WHO recently recommended research into “aqueous” extracts of Kava.


The objective of this study was to conduct the first documented human clinical trial assessing the anxiolytic and antidepressant efficacy of an aqueous extract of Kava.

Design and participants

The Kava Anxiety Depression Spectrum Study was a 3-week placebo-controlled, double-blind crossover trial that recruited 60 adult participants with 1 month or more of elevated generalized anxiety. Five Kava tablets per day were prescribed containing 250 mg of kavalactones/day.


The aqueous extract of Kava reduced participants' Hamilton Anxiety Scale score in the first controlled phase by −9.9 (CI = 7.1, 12.7) vs. −0.8 (CI = −2.7, 4.3) for placebo and in the second controlled phase by −10.3 (CI = 5.8, 14.7) vs. +3.3 (CI = −6.8, 0.2). The pooled effect of Kava vs. placebo across phases was highly significant (p < 0.0001), with a substantial effect size (d = 2.24, \( \eta_{\text{p}}^2 = 0.428 \)). Pooled analyses also revealed highly significant relative reductions in Beck Anxiety Inventory and Montgomery–Asberg Depression Rating Scale scores. The aqueous extract was found to be safe, with no serious adverse effects and no clinical hepatotoxicity.


The aqueous Kava preparation produced significant anxiolytic and antidepressant activity and raised no safety concerns at the dose and duration studied. Kava appears equally effective in cases where anxiety is accompanied by depression. This should encourage further study and consideration of globally reintroducing aqueous rootstock extracts of Kava for the management of anxiety.


Kava Piper methysticum Herbal medicine Aqueous extract Anxiety Depression 



Thanks are extended to Peter O’Rourke and Kylie Mallitt for their assistance with analyzing the data and to Ashley Dowell and the Centre for Phytochemistry and Pharmacology at Southern Cross University (Lismore Australia) for providing HPLC analysis of the Kava tablets.

Conflicts of interest

Kerry Bone is a consultant to MediHerb Pty Ltd (supplier of the tablets). He was not involved in the conduct of the study or the analysis of the data.


  1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:21–27PubMedGoogle Scholar
  2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th 'text revision' edn. American Psychiatric AssociationGoogle Scholar
  3. Beck AT, Ward C, Mendelson M (1961) Beck depression inventory (BDI). Arch Gen Psychiatry 4:561–571PubMedGoogle Scholar
  4. Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897PubMedCrossRefGoogle Scholar
  5. Blumenthal (2004) The ABC clinical guide to herbs. American Botanical CouncilGoogle Scholar
  6. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M (2003) Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder—an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 10(Suppl 4):38–49PubMedCrossRefGoogle Scholar
  7. Chouinard G (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65(Suppl 5):7–12PubMedGoogle Scholar
  8. Clouatre DL (2004) Kava kava: examining new reports of toxicity. Toxicol Lett 150:85–96PubMedCrossRefGoogle Scholar
  9. Coulter D (2007) Assessment of the risk of hepatotoxicity with kava products. WHO Appointed CommitteeGoogle Scholar
  10. Currie B, Clough A (2003) Kava hepatotoxicity with western herbal products: does it occur with traditional kava use? MJA 178:412–422Google Scholar
  11. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305–322PubMedCrossRefGoogle Scholar
  12. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedGoogle Scholar
  13. Kessler RC, Keller MB, Wittchen HU (2001) The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 24:19–39PubMedCrossRefGoogle Scholar
  14. Lebot V (2006) The quality of Kava consumed in the South Pacific. HerbalGram 71:34–37Google Scholar
  15. Lecrubier Y (2007) Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies. J Clin Psychiatry 68(Suppl 2):36–41PubMedGoogle Scholar
  16. Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C (2007) Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 21:774–782PubMedCrossRefGoogle Scholar
  17. Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P, So J, Burka LT (2005) Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 33:1555–1563PubMedCrossRefGoogle Scholar
  18. Mitte K, Noack P, Steil R, Hautzinger M (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141–150PubMedCrossRefGoogle Scholar
  19. Montgomery S, Asberg M (1979) New depression scale designed to be sensitive to change. Br J Psychiatry Suppl 134:382–389CrossRefGoogle Scholar
  20. Morris S (2008) Estimating effect sizes from pretest–posttest–control group designs. Organ Res Methods 11:364–386CrossRefGoogle Scholar
  21. Nerurkar P, Dragull K, Tang C (2004) In vitro toxicity of Kava alkaloid, pipermethysticine, in HepG2 cells compared to kavalactones. Toxicol Sci 79:106–111PubMedCrossRefGoogle Scholar
  22. Pittler MH, Ernst E (2000) Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20:84–89PubMedCrossRefGoogle Scholar
  23. Pittler MH, Ernst E (2006) Kava extract for treating anxiety. Cochrane Database Syst Rev: CD003383Google Scholar
  24. Posternak MA, Zimmerman M (2005) Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66:148–158PubMedCrossRefGoogle Scholar
  25. Rickels K, Rynn M (2002) Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14):9–16PubMedGoogle Scholar
  26. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablensky A, Pickens R, Regier DA, Sartorius N, Towle LH (1989) The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069–1077Google Scholar
  27. Sarris J, Kavanagh DJ, Deed G, Bone KM (2009) St. John’s wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum Psychopharmacol 24:41–48PubMedCrossRefGoogle Scholar
  28. Singh YN, Devkota AK (2003) Aqueous kava extracts do not affect liver function tests in rats. Planta Med 69:496–499PubMedCrossRefGoogle Scholar
  29. Stevinson C, Huntley A, Ernst E (2002) A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 25:251–261PubMedCrossRefGoogle Scholar
  30. Thompson R, Ruch W, Hasenöhrl R (2004) Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava). Hum Psychopharmacol 19:243–250PubMedCrossRefGoogle Scholar
  31. Tyrer P, Baldwin D (2006) Generalised anxiety disorder. Lancet 368:2156–2166PubMedCrossRefGoogle Scholar
  32. Vanuatu Kava Act (2002) Republic of Vanuatu No.7Google Scholar
  33. Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162–171PubMedCrossRefGoogle Scholar
  34. Witte S, Loew D, Gaus W (2005) Meta-analysis of the efficacy of the acetonic Kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 19:183–188PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • J. Sarris
    • 1
    Email author
  • D. J. Kavanagh
    • 2
  • G. Byrne
    • 1
  • K. M. Bone
    • 3
  • J. Adams
    • 4
  • G. Deed
    • 1
  1. 1.School of MedicineThe University of QueenslandBrisbaneAustralia
  2. 2.Institute of Health and Biomedical InnovationQueensland University of TechnologyBrisbaneAustralia
  3. 3.School of HealthUniversity of New EnglandArmidaleAustralia
  4. 4.School of Population HealthThe University of QueenslandBrisbaneAustralia

Personalised recommendations